HOME >> MEDICINE >> NEWS
Use of antibiotic to treat infectious eye disease trachoma may increase risk for reinfection

Use of the antibiotic azithromycin to treat trachoma in Vietnam resulted in an increase in the risk of re-infections, according to a study in the September 27 issue of JAMA.

In 1995, the World Health Organization (WHO) first published data on global blindness and reported that 15 percent of cases were due to trachoma (a contagious bacterial eye disease in which scar tissue forms inside the eyelid and causes infection), making it the second major cause of blindness after cataract. At that time, the WHO estimated that 146 million individuals were in need of treatment for active trachoma to prevent blindness, 10 million were in need of surgery for trachomatous trichiasis (eyelash[es] touching the eye), and 8 million were already blind, according to background information in the article.

In 1996, the WHO designed the SAFE (Surgery for trachomatous trichiasis; Antibiotics for Chlamydia trachomatis (a type of Chlamydia that causes trachoma); Facial cleanliness; and Environmental improvement) strategy with the goal of elimination of blinding trachoma by the year 2020. For the antibiotic arm of the SAFE strategy, the WHO has recommended antibiotic treatment with either topical tetracycline or oral azithromycin for certain categories of patients with active trachoma. Oral azithromycin has become the drug of choice for the SAFE programs because of difficulties concerning administration and adherence with topical tetracycline eye ointment. Despite a number of studies, there has been a lack of sufficient follow-up beyond the final treatment point to determine rates of recurrence of disease and infection and the risk factors that may contribute to each.

Berna Atik, M.D., M.P.H., of Children's Hospital Oakland Research Institute, Oakland, Calif., and colleagues evaluated the effect of targeted oral azithromycin treatment of school age children and their household members in Vietnam on active trachoma and C trachomatis infection rates. Vietnam is
'"/>

Contact: Venita Robinson
510-428-3069
JAMA and Archives Journals
26-Sep-2006


Page: 1 2

Related medicine news :

1. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
2. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
3. Plants uptake antibiotics
4. Community-associated staph infections involving antibiotic-resistant bacteria increase
5. Researchers discover how antibiotic inhibits bacterial growth
6. Study finds antibiotic resistance in poultry even when antibiotics were not used
7. Rapid flu testing is associated with decreased antibiotic use in hospitalized adults
8. Rapid flu tests may reduce threat of antibiotic resistance
9. Antibiotic ear drops favored over popular oral antibiotics for ear infections
10. Controlling antibiotics and antibiotic resistance in hospitals
11. Transmission of antibiotic-resistant bacteria linked to previous intensive care unit room occupants

Post Your Comments:
(Date:3/5/2015)... 05, 2015 Central Nebraska Imaging (CNI) ... including the brand’s new logo and optimized website. ... practice’s modern approach to expert diagnostic imaging, centered on ... be built to be a resource for Nebraska patients ... automated forms, communication and referral functionality, video content and ...
(Date:3/5/2015)... Santa Rosa, CA (PRWEB) March 05, 2015 ... Like a SuperPro! The series aims to teach viewers ... indoor garden with hydroponics. Grow Like a SuperPro takes you ... in between. From how to clone, to how to prune ... of growing. They are offering the whole series for download ...
(Date:3/5/2015)... March 05, 2015 Califia Farms ... announced at Natural Products Expo West that its popular ... 100 percent soy and dairy free. Califia Farms Vegan ... bottle and are packed with six grams of an ... includes fiber, B vitamins and magnesium. , Protein is ...
(Date:3/5/2015)... Diego, CA (PRWEB) March 05, 2015 ... the purest and most essential ingredients, the robust flavor ... of allergic reactions. PASCHA Chocolate is free from ... and sesame. Experience PASCHA's offering March 6th- 8th at ... Chocolate Spread. PASCHA Chocolate has broken new ground ...
(Date:3/5/2015)... 05, 2015 Today, Earth Source ... on 100% pollution-free electricity through a partnership with ... As an Arcadia Power Clean Energy Partner, ESO ... Power Partnership requirements, joining national brands such as ... clean energy. Earth Source Organics joins a growing ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2
(Date:3/5/2015)... and HAMPTON, N.J. , March ... MNK ), a leading global specialty biopharmaceutical ... announced today that they have entered into a definitive ... Ikaria, Inc. from a Madison Dearborn -led investor ... Subject to customary closing conditions, the ...
(Date:3/5/2015)... March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, announced today that Atlanta ... rehabilitation hospitals for spinal cord injury and brain injury, ... of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients ... (SCI). The Phase 1/2a trial follows ...
(Date:3/5/2015)... March 5, 2015  MGC Diagnostics Corporation (NASDAQ: ... company, today reported financial results for the first ... 2015 first quarter domestic equipment, supplies and accessories ... $3.7 million in the 2014 first quarter.  During ... or $338,000 in revenue, compared to 14 accounts, ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 3MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 4MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 5MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 6MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 7MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 8MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 9MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 10MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 11MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 12
Cached News: